Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.
Cytokinetics (NASDAQ: CYTK) presented Saturday August 29, 2026 additional results from the Phase 3 ACACIA-HCM (Myqorzo aficamten for non-obstructive HCM) and MAPLE-HCM trials in a Late-Breaking Clinical Trial Session at ESC Congress 2026 Munich, with simultaneous publications in Circulation and Journal of the American College of Cardiology: Heart Failure. The ACACIA-HCM additional analyses examined improvements in cardiac structure and diastolic function in patients with non-obstructive HCM (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), extending the primary readout (KCCQ Clinical Summary Score and peak VO2) presented in the Hot Line Session Friday August 28 and simultaneously published in NEJM. The follow-up data strengthens the aficamten commercial case for supplemental NDA in Q4 2026 and continues to differentiate the cardiac myosin inhibitor mechanism from mavacamten (Camzyos, Bristol Myers Squibb) which is currently approved only for obstructive HCM.
Alnylam Pharmaceuticals (NASDAQ: ALNY) presented Saturday August 29 and Sunday August 30, 2026 late-breaking prespecified subgroup analyses from the Phase 3 HELIOS-B trial of vutrisiran (AMVUTTRA, an RNAi therapeutic targeting transthyretin for transthyretin amyloidosis with cardiomyopathy, ATTR-CM) at ESC Congress 2026 Munich. Vutrisiran demonstrated consistent clinical benefit across all-cause mortality and recurrent cardiovascular events in patients with or without background tafamidis (the transthyretin tetramer stabilizer marketed as Vyndaqel/Vyndamax by Pfizer). The HELIOS-B trial had documented 28.2% reduction in all-cause mortality and 32.8% reduction in cardiovascular events with vutrisiran plus stabilizer. Additional analyses examined healthy aging, functional capacity, safety, and outcomes by sex. Alnylam also presented Amylo'ExTTRa, a large real-world analysis from the French National Health Data System characterizing the multisystem burden of ATTR-CM beyond cardiac manifestations. Vutrisiran anchors Alnylam's ATTR franchise alongside inclisiran (Leqvio, licensed to Novartis for hypercholesterolemia) and zilebesiran (Phase 3 ZENITH trial in hypertension).
The Factor XIa inhibitor milvexian (an oral small-molecule antithrombotic co-developed by Bristol Myers Squibb (NYSE: BMY) and Janssen) failed to reduce major adverse cardiovascular events versus placebo when added to standard antiplatelet therapy after recent acute coronary syndrome (ACS) in the Phase 3 LIBREXIA ACS trial presented in a Hot Line Session at ESC Congress 2026 Saturday August 29. The primary endpoint (cardiovascular death, myocardial infarction, or ischemic stroke) occurred in 5.4% of the milvexian arm versus 5.1% on placebo. Researchers observed no differences in intracranial or fatal bleeding between arms, addressing safety concerns that have historically constrained anticoagulant use in the post-ACS setting. The LIBREXIA program continues to assess milvexian in stroke and atrial fibrillation. The Factor XIa class as a whole (also including Bayer-Janssen's asundexian and Anthos Therapeutics' abelacimab) has struggled to demonstrate clean cardiovascular benefit at low bleeding cost.
The STAREE trial (a double-blind Australian primary-prevention trial in adults 70 and older) presented Saturday August 29, 2026 at ESC Congress 2026 Munich and simultaneously published in NEJM showed atorvastatin 40 mg daily reduced major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization) by approximately 30% versus placebo over 5.9 years median follow-up in 9,971 participants (mean age 74.7, 52% women). The co-primary endpoint of disability-free survival (survival free of dementia and physical disability) did not reach statistical significance. Muscle, liver, and diabetes-related adverse events were more common on atorvastatin, though serious adverse events were balanced. STAREE addresses a long-standing evidence gap on statin efficacy in older adults without known cardiovascular disease, diabetes, or dementia. Not a peptide, but the trial matters for peptide-industry readers because it reframes the primary-prevention benefit-risk calculus that will need to be modeled for cardiovascular outcome trials of peptide obesity therapies in older populations.
Cytokinetics (NASDAQ: CYTK) presented Friday August 28, 2026 the full results from the Phase 3 ACACIA-HCM trial of Myqorzo (aficamten, a next-generation cardiac myosin inhibitor) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026 in Munich, Germany, with simultaneous publication in The New England Journal of Medicine. The trial met both dual primary endpoints with statistically significant improvements from baseline to Week 36 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and peak oxygen uptake (peak VO2) versus placebo, plus improvements on key secondary endpoints. LVEF <50% occurred in 10% of aficamten patients vs 1% on placebo, with rare treatment interruptions due to LVEF <40% and two serious heart failure adverse events associated with LVEF <50%. Cytokinetics plans to submit a Supplemental New Drug Application in Q4 2026. There are no currently-approved therapies for non-obstructive HCM, and the ACACIA readout positions aficamten as the potential first-in-class treatment for this indication after the July 2026 initial obstructive-HCM approval.